近年来随着非小细胞肺癌靶向治疗快速发展，传统化疗获得的关注越来越少，而如何定位并合理地应用传统化疗药物，使患者从中得到最大的获益，在当前仍是不可忽视的命题。为此，通过对相关文献的回顾和分析，本文指出无论有无驱动基因突变的患者，传统化疗仍有许多不可替代之处，并且演变出了一些新的治疗模式，进一步提高了患者的生存获益，从而明确了靶向治疗背景下传统化疗的地位。同时通过对化疗疗效预测分子标志物研究和发展的阐述，指出未来传统化疗必将“靶向化”的发展方向。%In recent years, along with rapid development of targeted therapy in non-small cell lung cancer, tradi-tional chemotherapy get less and less attention. Yet it still can not be ignored in the current that how to locate and use tradi-tional chemotherapy so patients could derive maximum beneift. For this purpose, through the literature review and analysis, we point out there are still many traditional chemotherapy irreplaceable places whatever patients’ driver gene status. And there are some new treatment modalities of traditional chemotherapy which have been developed to further improve patients’ survival. At the same time, through exposition of predictive bio-markers development in chemotherapy, we pointed out that the future of traditional chemotherapy must be part of“targeted therapy”.
展开▼
